Clinical trial
Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial
NCT02619994 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- June 30, 2021
- Enrollment
- 214 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.